Cover Page
Cover Page - shares | 9 Months Ended | |
Sep. 26, 2020 | Nov. 02, 2020 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Sep. 26, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q3 | |
Trading Symbol | SCON | |
Entity Registrant Name | SUPERCONDUCTOR TECHNOLOGIES INC | |
Entity Central Index Key | 0000895665 | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Shell Company | false | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Title of 12(b) Security | Common Stock | |
Security Exchange Name | NONE | |
Entity Address, State or Province | TX | |
Entity Common Stock, Shares Outstanding | 3,151,780 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 26, 2020 | Sep. 28, 2019 | Sep. 26, 2020 | Sep. 28, 2019 | |
Total revenues | $ 157,000 | $ 184,000 | $ 157,000 | |
Costs and expenses: | ||||
Research and development | 622,000 | 178,000 | 1,875,000 | |
Selling, general and administrative | $ 606,000 | 966,000 | 2,176,000 | 2,922,000 |
Total costs and expenses | 606,000 | 2,541,000 | 2,615,000 | 7,512,000 |
Loss from operations | (606,000) | (2,384,000) | (2,431,000) | (7,355,000) |
Other income and expense: | ||||
Other income | 9,000 | 2,000 | 54,000 | |
Net loss | $ (606,000) | $ (2,375,000) | $ (2,429,000) | $ (7,301,000) |
Basic and diluted net loss per common share | $ (0.19) | $ (4.32) | $ (0.97) | $ (16.39) |
Basic and diluted weighted average number of common shares outstanding | 3,116,291 | 550,157 | 2,510,556 | 445,525 |
Commercial Product Revenues [Member] | ||||
Total revenues | $ 10,000 | |||
Costs and expenses: | ||||
Cost of revenues | $ 943,000 | 190,000 | $ 2,688,000 | |
Government Contract Revenues [Member] | ||||
Total revenues | 157,000 | 174,000 | 157,000 | |
Costs and expenses: | ||||
Cost of revenues | $ 10,000 | $ 71,000 | $ 27,000 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Sep. 26, 2020 | Dec. 31, 2019 |
Current Assets: | ||
Cash and cash equivalents | $ 1,762,000 | $ 713,000 |
Accounts receivable, net | 344,000 | |
Inventories, net | 68,000 | 263,000 |
Prepaid expenses and other current assets | 134,000 | 76,000 |
Total Current Assets | 1,964,000 | 1,396,000 |
Preferred equity interest in real estate | 1,600,000 | |
Property and equipment, net | 233,000 | |
Patents, licenses and purchased technology, net | 641,000 | |
Operating lease assets | 152,000 | |
Other assets | 60,000 | |
Total Assets | 3,564,000 | 2,482,000 |
Current Liabilities: | ||
Accounts payable | 212,000 | 527,000 |
Accrued expenses | 134,000 | 292,000 |
Current operating lease liabilities | 148,000 | |
Total Current Liabilities | 346,000 | 967,000 |
Long term operating lease liabilities | 4,000 | |
Other long term liabilities | 8,000 | |
Total Liabilities | 346,000 | 979,000 |
Commitments and Contingencies (Notes 5 and 6) | ||
Stockholders' Equity: | ||
Preferred stock, $.001 par value, 2,000,000 shares authorized, 328,925 and 328,925 shares issued and outstanding, respectively | ||
Common stock, $.001 par value, 25,000,000 shares authorized, 3,151,780 and 1,773,189 shares issued and outstanding, respectively | 3,000 | 2,000 |
Capital in excess of par value | 334,617,000 | 330,474,000 |
Accumulated deficit | (331,402,000) | (328,973,000) |
Total Stockholders' Equity | 3,218,000 | 1,503,000 |
Total Liabilities and Stockholders' Equity | $ 3,564,000 | $ 2,482,000 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Sep. 26, 2020 | Dec. 31, 2019 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 2,000,000 | 2,000,000 |
Preferred stock, shares issued | 328,925 | 328,925 |
Preferred stock, shares outstanding | 328,925 | 328,925 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 25,000,000 | 25,000,000 |
Common stock, shares issued | 3,151,780 | 1,773,189 |
Common stock, shares outstanding | 3,151,780 | 1,773,189 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 26, 2020 | Sep. 28, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (2,429,000) | $ (7,301,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 38,000 | 704,000 |
Stock-based compensation expense | 65,000 | 70,000 |
Gain from the sale of patents, property and equipment | (510,000) | 0 |
Write-down of intangibles | 134,000 | 0 |
Obsolete inventory | 190,000 | 0 |
Changes in assets and liabilities: | ||
Accounts receivable | 344,000 | (157,000) |
Inventories | 5,000 | 26,000 |
Prepaid expenses and other current assets | 2,000 | (86,000) |
Accounts payable, accrued expenses and other current liabilities | (491,000) | (18,000) |
Net cash used in operating activities | (2,652,000) | (6,762,000) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Net proceeds from the sale of patents, property and equipment | 1,222,000 | 0 |
Net cash used in investing activities | 1,222,000 | 0 |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Net proceeds from the sale of common stock | 1,421,000 | |
Net proceeds from the exercise of warrants | 2,479,000 | |
Net cash provided by financing activities | 2,479,000 | 1,421,000 |
Net increase (decrease) in cash and cash equivalents | 1,049,000 | (5,341,000) |
Cash and cash equivalents at beginning of period | 713,000 | 5,616,000 |
Cash and cash equivalents at end of period | 1,762,000 | $ 275,000 |
NONCASH INVESTING AND FINANCING ACTIVITIES: | ||
Acquisition of preferred equity interest in real estate in exchange for common stock | $ 1,600,000 |
General
General | 9 Months Ended |
Sep. 26, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
General | 1. General Please see “Our Future Business” below regarding material information and updates to the following general business description. Superconductor Technologies Inc. (“STI” and together with our subsidiaries, “we” or “us”) was incorporated in Delaware on May 11, 1987. We developed and produced high temperature superconducting (HTS) materials and associated technologies. We have generated more than 100 patents as well as proprietary trade secrets and manufacturing expertise. Our initial superconducting products were completed in 1998, and we began delivery to a number of wireless network providers. In the following 14 years, our cost reducing efforts led to the invention of our proprietary, high-yield and high throughput HTS material deposition manufacturing process. From 2010 through October 2019, we transitioned our research and development efforts to adapting our proprietary HTS material deposition techniques to the production of our HTS Conductus ® In November 2016, we were selected as the prime recipient of the $4.5 million program award provided by the U.S. Department of Energy’s (DOE) Office of Energy Efficiency and Renewable Energy (EERE), on behalf of the Advanced Manufacturing Office, for its Next Generation Electric Machines (NGEM) program and, in June 2017, the related contract was finalized and we have commenced work under that contract. In early 2018, we announced the concentration of our future Conductus wire product development efforts on NGEM to capitalize on several accelerating energy megatrends. This refined focus is very synergistic with our program with the Department of Energy (DOE) award for the development of superconducting wire to enable NGEM. On October 29, 2019, we announced that our Board of Directors, supported by its management team, had commenced a process to explore strategic alternatives focused on maximizing shareholder value. Strategic alternatives considered included, among others, a strategic investment financing which would allow the company to pursue its business plan to commercialize the Conductus wire platform, a business combination such as a merger with another party, or a sale of STI. On January 28, 2020, we announced a cost reduction plan for the purpose of aligning our personnel needs and capital requirements as we explored strategic alternatives previously announced. We are maintaining operations of our Sapphire Cryocooler cryogenics initiatives while ceasing additional manufacturing of our HTS Conductus ® Our Future Business On February 26, 2020, we entered into a definitive merger agreement with Allied Integral United, Inc. (“Clearday”), a privately-held company dedicated to delivering next generation longevity care and wellness services (as amended, the “Merger Agreement”), whereby a wholly-owned subsidiary of STI will merge with and into Clearday in a stock-for-stock On May 12, 2020, the Merger Agreement was amended by the parties to (i) add a covenant that the parties shall use their commercially reasonable efforts to cause STI to at all times remain listed on the Nasdaq Capital Market (or higher tier) and that if STI ceases to be listed on the Nasdaq Capital Market then the parties shall (including after the closing of the Merger) use their commercially reasonable efforts to cause STI to become listed on either the Nasdaq Capital Market or the NYSE MKT as promptly as reasonably possible, (ii) remove the conditions to closing the Merger that Nasdaq must determine that all listing deficiencies have been cured and determine to approve the listing of STI’s common stock on the Nasdaq and remove any other provisions in the Merger Agreement of like effect, (iii) extend the “outside date” for the Merger to close until the close of business on September 21, 2020 and (iv) require a customary tax representation letter from STI as a closing condition. The merged company will focus on the development of Clearday’s non-residential non-residential STI’s Current Report on Form 8-K, The completion of the Merger is subject to customary conditions, including (i) adoption of the Merger Agreement by each of STI and Clearday stockholders, (ii) Nasdaq approval of continued listing of STI Common Stock under its applicable rules, including the rules applicable to its change of control listing application, (iii) the registration statement on Form S-4 STI also has several rights to terminate the Merger Agreement without paying or receiving a break-up break-up On April 1, 2020, the Company received notice that the Nasdaq Hearings Panel had determined to grant the Company’s request for continued listing in light of the Company’s planned merger with Clearday. The extension was subject to several conditions. On June 30, 2020, the Company and a wholly-owned subsidiary of Clearday (“Clearday Sub”) entered into a Securities Purchase Agreement (the “Purchase Agreement”), which was consummated on July 6, 2020, pursuant to which STI issued four hundred thousand (400,000) shares of STI Common Stock (without any warrants) in exchange for a preferred equity interest in real estate (described in the related Current Report on Form 8-K) On July 22, 2020, as a result of the increase to the Company’s equity from the aforementioned preferred stock transaction, the Nasdaq Hearings Panel confirmed that we had regained compliance with the equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). Separately from compliance with the Equity Rule, we were still required to evidence compliance with the bid price requirement in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) no later than September 18, 2020. Under Nasdaq rules, as adjusted for the April 2020 Nasdaq rule change to allow for the tolling of the compliance period for companies experiencing a deficiency regarding the Bid Price Rule, we had until September 18, 2020 to demonstrate compliance with the Bid Price Rule for 10 consecutive trading days. We called a special meeting of stockholders to be held on September 2, 2020, however, we had to adjourn the meeting several times and only obtained the requisite stockholder vote on September 9, 2020, and the reverse split became effective in the market on September 10, 2020, by which time we were unable to show compliance with the Bid Price Rule’s 10 consecutive trading day requirement on or before September 18, 2020. On September 28, 2020 we received a letter from the Nasdaq Hearing Panel (“Panel”) determining to delist our common stock from The Nasdaq Stock Market. As a result of the decision, suspension of trading in the shares was effective at the open of business on September 30, 2020. See “Subsequent Events The Panel indicated that the Nasdaq Stock Market will complete the delisting by filing a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission, after applicable appeal periods have lapsed. Our common stock is currently quoted on the OTCQB. We also announced that, although the “outside date” of our merger agreement with Clearday has expired, both the Company and Clearday intend to finalize an extension to the merger agreement and proceed with the merger. Clearday has agreed that the listing of our common stock on the Nasdaq is not a condition to the closing of the merger. There is no assurance that the parties will complete such negotiation successfully or conclude the merger. We intend to satisfy the Bid Price Rule by taking appropriate action as needed, including through completion of the previously announced and pending merger with Allied Integral United, Inc. (a/k/a Clearday), although there is no certainty that such actions will be completed in a timely manner or otherwise. In addition, there is no assurance that the SEC will declare our planned Form S-4 The Merger Agreement contains customary representations and warranties. The representations, warranties and covenants of each party set forth in the Merger Agreement have been made only for the purposes of, and were and are solely for the benefit of the parties to, the Merger Agreement, may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Merger Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Accordingly, the representations and warranties may not describe the actual state of affairs at the date they were made or at any other time, and investors should not rely on them as statements of fact. In addition, such representations and warranties (i) will not survive consummation of the Merger and (ii) were made only as of the date of the Merger Agreement or such other date as is specified in the Merger Agreement. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the parties’ public disclosures. Accordingly, the Merger Agreement is included with this filing only to provide investors with information regarding the terms of the Merger Agreement, and not to provide investors with any factual information regarding STI or Clearday, their respective affiliates or their respective businesses. The Merger Agreement should not be read alone, but should instead be read in conjunction with the other information regarding the STI, Clearday, their respective affiliates or their respective businesses, the Merger Agreement and the Merger that will be contained in, or incorporated by reference into, the Registration Statement, as well as in the Forms 10-K, 10-Q In connection with the proposed transaction between STI and Clearday, the parties intend to file relevant materials with the SEC, including a STI registration statement on Form S-4 “Subsequent Events” Subsequent to the announcement on January 28, 2020 about our cost reduction plan, we started the process of selling, in separate transactions, assets that we deemed non-essential When the transactions were completed we continue to hold production, R&D, and testing assets for our Sapphire cryocooler business, along with the of our intellectual property assets for that product and certain HTS patents. The proceeds from this series of transactions is expected to be sufficient, together with our other capital resources, for us to complete the Merger assuming it occurs without material additional delay. However, we would likely be unable to complete the Merger or continue operations if the Merger is not completed before the third quarter of 2021 unless we received additional financing, which is unlikely. If we do not proceed with the Merger, we would be likely to seek stockholder approval to sell our remaining assets and liquidate. Such a transaction, if it were to occur, would entail additional expenses and would likely leave minimal assets for distribution. As a result of these sales, we no longer have the ability to resume HTS wire operations without significant new investments and restructured operations and a new HTS wire business plan, neither of which we currently intend to pursue, as we instead focus our efforts on completing the Merger. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 26, 2020 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation We have incurred significant net losses since our inception and have an accumulated deficit of $331.4 million. In 2019, we incurred a net loss of $9.2 million and had negative cash flows from operations of $8.8 million. In the nine months ended September 26, 2020, we incurred a net loss of $2.4 million and had negative cash flows from operations of $2.7 million. At September 26, 2020, we had $1.8 million in cash and cash equivalents compared to $0.7 million in cash and cash equivalents as of December 31, 2019. In the nine months ended September 26, 2020, 978,594 warrants were exercised for common shares of our stock in connection with our October 2019 financing, providing us with $2.5 million. Our cash resources will be sufficient to fund our business through the end of the current fiscal year, but not sufficient to fund our business for the next twelve months. Therefore, unless we can successfully implement our strategic alternatives plan including, among others, a strategic investment financing which would allow us to pursue our current business plan, a business combination such as our merger with Clearday, or a sale of STI, we may need to raise additional capital to maintain our viability. Additional financing may not be available on acceptable terms or at all. If we issue additional equity securities to raise funds, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock. These factors raise substantial doubt about our ability to continue as a going concern. On September 10, 2020, we effected a 1-for-10 pre-Reverse In 2019, we undertook steps to reduce our ongoing operating costs and we raised net cash proceeds of $3.9 million from the sale of our common and preferred shares and warrants. On July 24, 2018, we effected a 1-for-10 stock split of our common stock (the “2019 Reverse Stock Split”). As a result of the 2019 Reverse Stock Split, every ten shares of our pre-2019 The accompanying condensed consolidated financial statements do not include any adjustments that may result from the outcome of the uncertainties set forth above. Principles of Consolidation The interim condensed consolidated financial statements include the accounts of Superconductor Technologies Inc. and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated from the condensed consolidated financial statements. Cash and Cash Equivalents Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less. Cash and cash equivalents are maintained with what we believe to be quality financial institutions and exceed FDIC limits. Historically, we have not experienced any losses due to such concentration of credit risk. Accounts Receivable We grant uncollateralized credit to our customers. We perform usual and customary credit evaluations of our customers before granting credit. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on historical write-off off-balance Revenue Recognition On January 1, 2018, we adopted ASC Topic 606, Revenue from Contracts with Customers Commercial and government contract revenues are recognized once all of the following conditions have been met: a) an authorized purchase order has been received in writing, b) the customer’s credit worthiness has been established, c) shipment of the product has occurred, d) title has transferred, and e) if stipulated by the contract, customer acceptance has occurred and all significant vendor obligations, if any, have been satisfied. Government contract revenues are principally generated under research and development contracts. Revenues from research-related activities are derived from contracts with agencies of the U.S. Government. Credit risk related to accounts receivable arising from such contracts is considered minimal. All payments to us for work performed on contracts with agencies of the U.S. Government are subject to adjustment upon audit by the Defense Contract Audit Agency. Based on historical experience and review of our current project in process, we believe that adjustments from open audits will not have an effect on our financial position, results of operations or cash flows. We are using the expected cost-plus-margin approach as the suitable method for allocating transaction price to the performance obligations in the contract under ASC 606. Leases At contract inception, we determine if an arrangement is a lease. Operating leases are included in “Operating lease assets”, “Current operating lease liabilities” and “Long term operating lease liabilities” on the condensed consolidated balance sheets. At March 31, 2020 all of our operating lease obligations had expired or were terminated. We have no finance leases. Leases with an initial term of 12 months or less were not recorded on the condensed consolidated balance sheets. Operating lease expense was recognized on a straight-line basis over the lease term. We had lease agreements with lease and non-lease non-lease Operating lease assets and liabilities were recognized at January 1, 2019, based on the present value of the future minimum lease payments over the lease term. One of our leases contained rent escalation clauses that were factored into our determination of lease payments. Our leases did not provide an implicit rate; we used its incremental borrowing rate based on the information available at the lease commencement date to discount payments to the present value. One of our operating leases contained a renewal option. The exercise of this option was at our discretion. Lease terms included options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Shipping and Handling Fees and Costs Shipping and handling fees billed to customers are included in net revenues. Shipping and handling fees associated with freight are generally included in cost of revenues. Warranties We offer warranties generally ranging from one to five years, depending on the product and negotiated terms of purchase agreements with our customers. Such warranties require us to repair or replace defective products returned to us during such warranty period at no cost to the customer. An estimate by us for warranty related costs is recorded by us at the time of sale based on our actual historical product return rates and expected repair costs. Such costs have been within our expectations. Indemnities In connection with the sales and manufacturing of our commercial products, we indemnify, without limit or term, our customers and contract manufacturers against all claims, suits, demands, damages, liabilities, expenses, judgments, settlements and penalties arising from actual or alleged infringement or misappropriation of any intellectual property relating to our products or other claims arising from our products. We cannot reasonably develop an estimate of the maximum potential amount of payments that might be made under our indemnities because of the uncertainty as to whether a claim might arise and how much it might total. Historically, we have not incurred any expenses related to these indemnities. Research and Development Costs Research and development costs are charged to expense as incurred and include salary, facility, depreciation and material expenses. Research and development costs are charged to research and development expense. Inventories Inventories were stated at the lower of cost or net realizable value, with costs primarily determined using standard costs, which approximate actual costs utilizing the first-in, first-out Preferred equity interest in real estate We entered into a Securities Purchase Agreement with Clearday, which was consummated on July 6, 2020, pursuant to which we an arm’s-length all-cash purchase Property and Equipment Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over their estimated useful lives ranging from three to five years. Leasehold improvements and assets financed under capital leases are amortized over the shorter of their useful lives. Furniture and fixtures are depreciated over seven years. Expenditures for additions and major improvements are capitalized. Expenditures for minor tooling, repairs and maintenance and minor improvements are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded in selling, general and administration expenses. During the three month period ending March 28, 2020 we ceased production of our Conductus wire and sold most of our production wire equipment for a gain of $510,000. There was no additional gain or loss in the three or nine month period ending September 26, 2020. Patents, Licenses and Purchased Technology Patents and licenses are recorded at cost and are amortized using the straight-line method over the shorter of their estimated useful lives or seventeen years. During the three month period ending March 28, 2020 we ceased production of our Conductus wire and sold many Conductus wire patents for no gain or loss and we also recognized a $134,000 impairment of other patents. There was no additional gain or loss in the three or nine month period ending September 26, 2020. Other Assets and Investments The realizability of long-lived assets is evaluated periodically as events or circumstances indicate a possible inability to recover the carrying amount. Long-lived assets that will no longer be used in the business are written off in the period identified since they will no longer be used in operations and generate any positive cash flows for us. Periodically, long-lived assets that will continue to be used by us will need to be evaluated for recoverability. Such evaluation is based on various analyses, including cash flow and profitability projections, as well as alternative uses, such as government contracts or awards. The analyses necessarily involve significant management judgment. In the event the projected undiscounted cash flows are less than net book value of the assets, the carrying value of the assets will be written down to their estimated fair value. We tested our long-lived assets at September 26, 2020 and none of our long-lived assets were impaired. Loss Contingencies In the normal course of our business, we are subject to claims and litigation, including allegations of patent infringement. Liabilities relating to these claims are recorded when it is determined that a loss is probable and the amount of the loss can be reasonably estimated. Legal fees are recorded as services are provided. The costs of our defense in such matters are charged to operations as incurred. Insurance proceeds recoverable are recorded when deemed probable. Income Taxes We recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized. two-step more-likely-than-not No liabilities for uncertain tax positions were recorded in the current year. No interest or penalties on uncertain tax positions have been expensed to date. We are not under examination by any taxing authorities. Our federal statute of limitations for examination of us is open for 2016 and subsequent filings. Due to our operating losses, the 2017 Tax Act has not impacted our operating results or income tax expense. The primary impact of the 2017 Tax Act was the re-measurement As of December 31, 2019, we had net operating loss carryforwards for federal and state income tax purposes. We concluded that under the Internal Revenue Code change of control limitations, a maximum of $17.9 million of our $342.4 net operating loss carryforwards, which expire in the years 2020 through 2038, would be available for reduction of taxable income and reduced both the deferred tax asset and valuation allowance accordingly. Due to the uncertainty surrounding their realization, we recorded a full valuation allowance against our net deferred tax assets. Accordingly, no deferred tax asset has been recorded in the accompanying condensed consolidated balance sheets. Marketing Costs All costs related to marketing and advertising our products are charged to expense as incurred or at the time the advertising takes place. Advertising costs were not material in each of the three and nine months ended September 26, 2020 and September 28, 2019. Net Loss Per Share Basic and diluted net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding in each year. Net loss available to common stockholders is computed after deducting accumulated dividends on cumulative preferred stock, deemed dividends and accretion of redemption value on redeemable preferred stock for the period and beneficial conversion features on issuance of convertible preferred stock. Potential common shares are not included in the calculation of diluted loss per share because their effect is anti-dilutive. Stock-based Compensation Expense We grant both restricted stock awards and stock options to our key employees, directors and consultants. For the three and nine months ended September 26, 2020 and September 28, 2019, no options or awards were granted. The following table presents details of total stock-based compensation expense that is included Three months ended Nine months ended September 26, September 28, September 26, September 28, Cost of revenue $ — $ 1,000 $ 2,000 $ 3,000 Research and development 3,000 2,000 7,000 7,000 Selling, general and administrative 19,000 20,000 56,000 60,000 Total stock-based compensation expense $ 22,000 $ 23,000 $ 65,000 $ 70,000 Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The significant estimates in the preparation of the financial statements relate to the assessment of the carrying amount of accounts receivable, fixed assets, intangibles, preferred equity interest in real estate, estimated provisions for warranty costs, income taxes and disclosures related to litigation. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements. Fair Value of Financial Instruments We have estimated the fair value amounts of our financial instruments using the available market information and valuation methodologies considered appropriate. We determined the book value of our cash and cash equivalents and other current liabilities as of September 26, 2020 approximate fair value. Comprehensive Income We have no items of other comprehensive income in any period and consequently have not included a Statement of Comprehensive Income. Segment Information We have historically operated in a single business segment: the research, development, manufacture and marketing of high performance products used in cellular base stations. We derived net commercial product revenues primarily from the sales of our AmpLink and SuperPlex products which we sold directly to wireless network operators in the United States. Net revenues derived principally from government contracts are presented separately on the consolidated statements of operations for all periods presented. As discussed in this Report, we no longer have the ability to resume HTS wire operations without significant new investments and restructured operations and a new HTS wire business plan, neither of which we currently intend to pursue, as we instead focus our efforts on completing the Merger. Certain Risks and Uncertainties On October 29, 2019, we announced that our Board of Directors, supported by its management team, had commenced a process to explore strategic alternatives focused on maximizing shareholder value. Strategic alternatives considered included, among others, a strategic investment financing which would allow the company to pursue its current business plan to commercialize the Conductus wire platform, a business combination such as a merger with another party, or a sale of STI. On January 28, 2020, we announced a cost reduction plan for the purpose of aligning our personnel needs and capital requirements as we explored strategic alternatives previously announced. We will maintain operations of our Sapphire Cryocooler cryogenics initiatives while ceasing additional manufacturing of our HTS Conductus ® On February 26, 2020, we entered into a definitive merger agreement Clearday a privately-held company dedicated to delivering next generation longevity care and wellness services, whereby a wholly-owned subsidiary of STI will merge with and into Clearday in a stock-for-stock See “Our Future Business” above and “Subsequent Events” for more information. |
Stockholders' Equity
Stockholders' Equity | 9 Months Ended |
Sep. 26, 2020 | |
Equity [Abstract] | |
Stockholders' Equity | 3. Stockholders’ Equity The following is a summary of stockholders’ equity transactions for the three and nine months ended September 26, 2020: Convertible Common Stock Capital in Par Value Accumulated Deficit Total Shares Amount Shares Amount Balance at June 27, 2020 328,925 $ — 2,750,955 $ 3,000 $ 332,993,000 $ (330,796,000 ) $ 2,200,000 Issuance of common Stock for a preferred equity interest in real estate 400,000 — 1,600,000 1,600,000 Warrant exercises 828 — 2,000 2,000 Stock-based compensation 22,000 22,000 Cancellation of shares from the reverse stock split (3 ) — Net loss (606,000 ) (606,000 ) Balance at September 26, 2020 328,925 $ — 3,151,780 $ 3,000 $ 334,617,000 $ (331,402,000 ) $ 3,218,000 Convertible Preferred Stock Common Stock Capital in Excess of Par Value Accumulated Deficit Total Shares Amount Shares Amount Balance at December 31, 2019 328,925 $ — 1,773,189 $ 2,000 $ 330,474,000 $ (328,973,000 ) $ 1,503,000 Issuance of common Stock for a preferred equity interest in real estate 400,000 — 1,600,000 1,600,000 Warrant exercises 978,594 1,000 2,478,000 2,479,000 Stock-based compensation 65,000 65,000 Cancellation of shares from the reverse stock split (3 ) — Net loss (2,429,000 ) (2,429,000 ) Balance at September 26, 2020 328,925 $ — 3,151,780 $ 3,000 $ 334,617,000 $ (331,402,000 ) $ 3,218,000 The following is a summary of stockholders’ equity transactions for the three and nine months ended September 28, 2019: Convertible Common Stock Capital in Par Value Accumulated Deficit Total Shares Amount Shares Amount Balance at June 29, 2019 328,925 $ — 550,260 $ 1,000 $ 327,956,000 $ (324,670,000 ) $ 3,287,000 Issuance of common stock (net of costs) — Stock-based compensation 23,000 23,000 Net loss (2,375,000 ) (2,375,000 ) Balance at September 28, 2019 328,925 $ — 550,260 $ 1,000 $ 327,979,000 $ (327,045,000 ) $ 935,000 Convertible Common Stock Capital in Par Value Accumulated Deficit Total Shares Amount Shares Amount Balance at December 31, 2018 330,787 $ — 327,060 $ 1,000 $ 326,488,000 $ (319,744,000 ) $ 6,745,000 Conversion of Series E preferred stock to common stock (1,862 ) — 53,200 — — — Issuance of common stock (net of costs) 170,000 — 1,421,000 1,421,000 Stock-based compensation 70,000 70,000 Net loss (7,301,000 ) (7,301,000 ) Balance at September 28, 2019 328,925 $ — 550,260 $ 1,000 $ 327,979,000 $ (327,045,000 ) $ 935,000 Stock Options At September 26, 2020, we had two active equity award option plans, the 2003 Equity Incentive Plan and the 2013 Equity Incentive Plan (collectively, the “Stock Option Plan”), although we can only grant new options under the 2013 Equity Incentive Plan. Under our Stock Option Plan, stock awards were made to our directors, key employees, consultants, and non-employee The impact to the condensed consolidated statements of operations for the three and nine months ended September 26, 2020 on net loss was $22,000 and $63,000 and $0.01 and $0.03 on basic and diluted net loss per common share, respectively, compared to $20,000 and $62,000 and $0.04 and $0.14 on basic and diluted net loss per common share for the three and nine months ended September 28, 2019. No stock compensation cost was capitalized during either period. The total compensation cost related to nonvested awards not yet recognized was $17,000 and the weighted-average period over which the cost is expected to be recognized was 3 months at September 26, 2020. The following is a summary of stock option transactions under our Stock Option Plans at September 26, 2020: Number of Price Per Share Weighted Number of Weighted Balance at December 31, 2019 13,725 $ 19.20 - $51,480 $ 252.00 7,450 $ 448.10 Granted — Exercised — Canceled 5,862 $ 19.20 - $51,480 246.80 3,162 441.10 Balance at September 26, 2020 7,863 $ 19.20 - $28,440 $ 255.90 4,288 $ 453.30 The outstanding options expire on various dates through the end of October 2028. The weighted-average contractual term of options outstanding is 7.7 years and the weighted-average contractual term of stock options currently exercisable is 7.4 years. The exercise prices for these options range from $19.20 to $28,440 per share, for an aggregate exercise price of $2 million. At September 26, 2020, no options had an exercise price less than the current market value. Restricted Stock Awards The grant date fair value of each share of our restricted stock awards is equal to the fair value of our common stock at the grant date. Shares of restricted stock under awards all have service conditions and vest over one to three years. The following is a summary of our restricted stock award transactions at September 26, 2020: Number of Weighted Average Grant Balance nonvested at December 31, 2019 33 $ 105.00 Granted — — Vested — — Forfeited — — Balance nonvested at September 26, 2020 33 $ 105.00 The impact to the condensed consolidated statements of operations for the three and nine months ended September 26, 2020 was $0 and $2,000 and $0.00 and $0.00, respectively, and $3,000 and $8,000 and $0.01 and $0.02 on basic and diluted net loss per common share for the three and nine months ended September 28, 2019, respectively. No stock compensation cost was capitalized during the period. There was no compensation cost related to nonvested awards not yet recognized at September 26, 2020. Warrants and Common Stock The following is a summary of outstanding warrants at September 26, 2020: Common Shares Total Currently Price per Expiration Date (1) Warrants related to October 2015 financing 13,552 13,552 $ 600.00 October 14, 2020 (2) Warrants related to October 2015 financing 903 903 $ 656.30 October 14, 2020 (3) Warrants related to August 2016 financing 5,350 5,350 $ 300.00 February 2, 2022 (4) Warrants related to August 2016 financing 500 500 $ 385.50 August 2, 2021 (5) Warrants related to December 2016 financing 68,567 68,567 $ 200.00 December 14, 2021 (6) Warrants related to March 2018 financing 15,810 15,810 $ 114.00 September 9, 2023 (7) Warrants related to March 2018 financing 1,107 1,107 $ 158.00 March 6, 2023 (8) Warrants related to July 2018 financing 257,143 257,143 $ 35.00 July 25, 2023 (9) Warrants related to July 2018 financing 15,428 15,428 $ 43.75 July 25, 2023 (10) Warrants related to May 2019 financing 11,900 11,900 $ 12.50 May 23, 2024 (11) Warrants related to October 2019 financing 217,200 217,200 $ 2.50 October 10, 2024 (12) Warrants related to October 2019 financing 30,916 30,916 $ 3.13 October 8, 2024 On October 10, 2019 we completed a public offering of an aggregate of 1,183,400 shares of our common stock (or common stock equivalents) and warrants to purchase an aggregate of 1,183,400 shares of common stock with gross proceeds to us of approximately $3.0 million. The warrants are exercisable for five years at an exercise price equal to the public offering price. The offering was priced at $2.50 per share of common stock. The net proceeds to us from the offering, after deducting the placement agent fees and our estimated offering expenses, was approximately $2.4 million. The placement agent received warrants to purchase 82,838 shares of common stock, at an exercise price of $3.125 that will expire October 8, 2024 and are subject to a six month lock-up. On May 23, 2019 we completed a public offering of an aggregate of 170,000 shares of our common stock with gross proceeds to us of $1.7 million. The offering was priced at $10.00 per share of common stock. The net proceeds to us from the offering, after deducting the placement agent fees and our estimated offering expenses, was approximately $1.4 million. The placement agent received warrants to purchase 11,900 shares of common stock, at an exercise price of $12.50, that are subject to a six month lock-up On July 30, 2018 we completed a public offering of an aggregate of 257,142 shares of our common stock (or common stock equivalents initially in the form of Series E Preferred Stock) and warrants to purchase an aggregate of 257,142 shares of common stock with gross proceeds to us of $9.0 million. The net proceeds to us from the offering, after deducting the placement agent fees and our estimated offering expenses, was $7.98 million. The offering was priced at $35.00 per share of common stock (or common stock equivalent), with each share of common stock (or common stock equivalent) sold with one five-year warrant to purchase one share of common stock, at an exercise price of $35.00 per share. The placement agent also received warrants to purchase 15,428 shares of common stock, at an exercise price of $43.75, that are subject to a six month lock-up On March 7, 2018, we announced the pricing of a registered offering of common stock (and common stock equivalents) with total gross proceeds of approximately $2 million. The closing of the registered public offering was completed on March 9, 2018. The net proceeds to us from the registered offering, after deducting the placement agent fees and our estimated offering expenses, was $1.7 million. In a concurrent private placement, we issued to the investor in the registered offering, an unregistered warrant (the “Warrants”) to purchase one share of common stock for each share of common stock or Pre-funded Our warrants are exercisable by paying cash or, solely in the absence of an effective registration statement or prospectus, by cashless exercise for unregistered shares of common stock. The exercise price of the warrants is subject to standard antidilutive provision adjustment in the case of stock dividends or other distributions on shares of common stock or any other equity or equity equivalent securities payable in shares of common stock, stock splits, stock combinations, reclassifications or similar events affecting our common stock, and also, subject to limitations, upon any distribution of assets, including cash, stock or other property to our stockholders. The exercise price of the warrants is not subject to “price-based” anti-dilution adjustment. We have determined that these warrants related to issuance of common stock are subject to equity treatment because the warrant holder has no right to demand cash settlement and there are no unusual anti-dilution rights. Securities Purchase Agreement We entered into a Securities Purchase Agreement with Clearday, which was consummated on July 6, 2020, pursuant to which we an arm’s-length all-cash purchase |
Loss Per Share
Loss Per Share | 9 Months Ended |
Sep. 26, 2020 | |
Earnings Per Share [Abstract] | |
Loss Per Share | 4. Loss Per Share Basic and diluted net loss per share is based on the weighted-average number of common shares outstanding. Since their impact would be anti-dilutive, our net loss per common share does not include the effect of the assumed exercise or vesting of the following shares: September 26, September 28, Outstanding stock options 7,863 13,782 Unvested restricted stock awards 33 33 Outstanding warrants 638,376 391,414 Total 646,272 405,229 Also, the preferred stock convertible into 182 shares of common stock was not included since its impact would be anti-dilutive. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 26, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 5. Commitments and Contingencies Operating Leases We leased our offices and production facility under a non-cancelable For the three and nine months ended September 26, 2020, operating lease expense was $0 and $143,000. As of March 28, 2020 we had no remaining operating lease obligations. Patents and Licenses We had entered into various licensing agreements requiring royalty payments ranging from 0.13% to 2.5% of specified product sales. Certain of these agreements contained provisions for the payment of guaranteed or minimum royalty amounts. Our minimum license obligations were $10,000 per year through 2025. In the event that we fail to pay minimum annual royalties, these licenses may automatically become non-exclusive |
Contractual Guarantees and Inde
Contractual Guarantees and Indemnities | 9 Months Ended |
Sep. 26, 2020 | |
Text Block [Abstract] | |
Contractual Guarantees and Indemnities | 6. Contractual Guarantees and Indemnities During our normal course of business, we make certain contractual guarantees and indemnities pursuant to which we may be required to make future payments under specific circumstances. We have not recorded any liability for these contractual guarantees and indemnities in the accompanying condensed consolidated financial statements. Warranties We establish reserves for future product warranty costs that are expected to be incurred pursuant to specific warranty provisions with our customers. Our warranty reserves are established at the time of sale and updated throughout the warranty period based upon numerous factors including historical warranty return rates and expenses over various warranty periods. Intellectual Property Indemnities We indemnify certain customers and our contract manufacturers against liability arising from third-party claims of intellectual property rights infringement related to our products. These indemnities appear in development and supply agreements with our customers as well as manufacturing service agreements with our contract manufacturers, are not limited in amount or duration and generally survive the expiration of the contract. Given that the amount of potential liabilities related to such indemnities cannot be determined until an infringement claim has been made, we are unable to determine the maximum amount of losses that we could incur related to such indemnities. Director and Officer Indemnities and Contractual Guarantees We have entered into indemnification agreements with our directors and executive officers which require us to indemnify such individuals to the fullest extent permitted by Delaware law. Our indemnification obligations under such agreements are not limited in amount or duration. Certain costs incurred in connection with such indemnities may be recovered under certain circumstances under various insurance policies. Given that the amount of any potential liabilities related to such indemnities cannot be determined until a lawsuit has been filed against a director or executive officer, we are unable to determine the maximum amount of losses that we could incur relating to such indemnities. Historically, any amounts payable pursuant to such director and officer indemnities have not had a material negative effect on our business, financial condition or results of operations. We have also entered into severance and change in control agreements with certain of our executives. These agreements provide for the payment of specific compensation benefits to such executives upon the termination of their employment with us. General Contractual Indemnities/Products Liability During the normal course of business, we enter into contracts with customers where we agree to indemnify the other party for personal injury or property damage caused by our products. Our indemnification obligations under such agreements are not generally limited in amount or duration. Given that the amount of any potential liabilities related to such indemnities cannot be determined until a lawsuit has been filed, we are unable to determine the maximum amount of losses that we could incur relating to such indemnities. Historically, any amounts payable pursuant to such indemnities have not had a material negative effect on our business, financial condition or results of operations. We maintain general and product liability insurance as well as errors and omissions insurance which may provide a source of recovery to us in the event of an indemnification claim. |
Details of Certain Financial St
Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Activities | 9 Months Ended |
Sep. 26, 2020 | |
Text Block [Abstract] | |
Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Activities | 7. Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Balance Sheet Data September 26, December 31, Accounts receivable: Accounts receivable-commercial products $ — $ 347,000 Less: allowance for doubtful accounts — (3,000 ) $ — $ 344,000 September 26, December 31, Inventories: Raw materials $ — $ 152,000 Work In Process 68,000 111,000 $ 68,000 $ 263,000 September 26, December 31, Property and Equipment: Equipment $ 316,000 $ 11,911,000 Leasehold improvements — 1,065,000 Furniture and fixtures — 205,000 316,000 13,181,000 Less: accumulated depreciation and amortization (316,000 ) (12,948,000 ) $ — $ 233,000 Depreciation expense amounted to $0 and $224,000, respectively, for the three and nine month periods ended September 26, 2020 and $224,000 and $671,000, respectively, for the three and nine months ended September 28, 2019. September 26, December 31, Patents and Licenses: Patents pending $ — $ — Patents issued 278,000 1,712,000 Less accumulated amortization (278,000 ) (1,071,000 ) Net patents issued — 641,000 $ — $ 641,000 Amortization expense related to these items totaled $0 and $11,000, respectively, for the three and nine months ended September 26, 2020 and $11,000 and $33,000, respectively, for the three and nine months ended September 28, 2019. No amortization expense is expected for the remainder of 2020, 2021 and 2022. September 26, December 31, 2019 Accrued Expenses and Other Long Term Liabilities: Salaries Payable $ 14,000 $ 23,000 Compensated absences 90,000 211,000 Compensation related — 4,000 Warranty reserve — 8,000 Operating lease — 152,000 Other 30,000 54,000 134,000 452,000 Less current portion (134,000 ) (440,000 ) Long term portion $ — $ 12,000 For the nine months ended, September 26, September 28, Warranty Reserve Activity: Beginning balance $ 8,000 $ 8,000 Additions — — Deductions 8,000 — Ending balance $ — $ 8,000 |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 26, 2020 | |
Subsequent Events [Abstract] | |
Subsequent Events | 8. Subsequent Events On September 30, 2020 we announced that we received a letter from the Nasdaq Hearing Panel (“Panel”) determining to delist our common stock from The Nasdaq Stock Market. As a result of the decision, suspension of trading in our As previously disclosed, we appealed to the Panel on February 27, 2020 due to its failure to maintain compliance with Nasdaq’s minimum closing bid price rule (“Bid Price Rule”) and minimum $2.5 million in shareholder equity (“Shareholder Equity Rule”). We previously cured its Shareholder Equity Rule deficiency. Under Nasdaq rules, as adjusted for the April 2020 Nasdaq rule change to allow for the tolling of the compliance period for companies experiencing a deficiency regarding the Bid Price Rule, we had until September 18, 2020 to demonstrate compliance with the Bid Price Rule for 10 consecutive trading days. We called a special meeting of stockholders to be held on September 2, 2020, however, we had to adjourn the meeting several times and only obtained the requisite stockholder vote on September 9, 2020, and the reverse split became effective in the market on September 10, 2020, by which time we were unable to show compliance with the Bid Price Rule’s 10 consecutive trading day requirement on or before September 18, 2020. The Panel indicated that the Nasdaq Stock Market will complete the delisting by filing a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission, after applicable appeal periods have lapsed. Our common stock is currently quoted on the OTCQB. We also announced that, although the “outside date” of our merger agreement with Clearday has expired, both the Company and Clearday intend to finalize an extension to the merger agreement and proceed with the merger. Clearday has agreed that the listing of our common stock on the Nasdaq is not a condition to the closing of the merger. Although Clearday has, subsequent to September 30, 2020, delivered substantially final financial statements for its 2019 fiscal year and the six months ended June 30, 2020, which are being reviewed by us, there is no assurance that the parties will complete such negotiation successfully or conclude the merger. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 26, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation We have incurred significant net losses since our inception and have an accumulated deficit of $331.4 million. In 2019, we incurred a net loss of $9.2 million and had negative cash flows from operations of $8.8 million. In the nine months ended September 26, 2020, we incurred a net loss of $2.4 million and had negative cash flows from operations of $2.7 million. At September 26, 2020, we had $1.8 million in cash and cash equivalents compared to $0.7 million in cash and cash equivalents as of December 31, 2019. In the nine months ended September 26, 2020, 978,594 warrants were exercised for common shares of our stock in connection with our October 2019 financing, providing us with $2.5 million. Our cash resources will be sufficient to fund our business through the end of the current fiscal year, but not sufficient to fund our business for the next twelve months. Therefore, unless we can successfully implement our strategic alternatives plan including, among others, a strategic investment financing which would allow us to pursue our current business plan, a business combination such as our merger with Clearday, or a sale of STI, we may need to raise additional capital to maintain our viability. Additional financing may not be available on acceptable terms or at all. If we issue additional equity securities to raise funds, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock. These factors raise substantial doubt about our ability to continue as a going concern. On September 10, 2020, we effected a 1-for-10 pre-Reverse In 2019, we undertook steps to reduce our ongoing operating costs and we raised net cash proceeds of $3.9 million from the sale of our common and preferred shares and warrants. On July 24, 2018, we effected a 1-for-10 stock split of our common stock (the “2019 Reverse Stock Split”). As a result of the 2019 Reverse Stock Split, every ten shares of our pre-2019 The accompanying condensed consolidated financial statements do not include any adjustments that may result from the outcome of the uncertainties set forth above. |
Principles of Consolidation | Principles of Consolidation The interim condensed consolidated financial statements include the accounts of Superconductor Technologies Inc. and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated from the condensed consolidated financial statements. |
Cash and Cash Equivalents | Cash and Cash Equivalents Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less. Cash and cash equivalents are maintained with what we believe to be quality financial institutions and exceed FDIC limits. Historically, we have not experienced any losses due to such concentration of credit risk. |
Accounts Receivable | Accounts Receivable We grant uncollateralized credit to our customers. We perform usual and customary credit evaluations of our customers before granting credit. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on historical write-off off-balance |
Revenue Recognition | Revenue Recognition On January 1, 2018, we adopted ASC Topic 606, Revenue from Contracts with Customers Commercial and government contract revenues are recognized once all of the following conditions have been met: a) an authorized purchase order has been received in writing, b) the customer’s credit worthiness has been established, c) shipment of the product has occurred, d) title has transferred, and e) if stipulated by the contract, customer acceptance has occurred and all significant vendor obligations, if any, have been satisfied. Government contract revenues are principally generated under research and development contracts. Revenues from research-related activities are derived from contracts with agencies of the U.S. Government. Credit risk related to accounts receivable arising from such contracts is considered minimal. All payments to us for work performed on contracts with agencies of the U.S. Government are subject to adjustment upon audit by the Defense Contract Audit Agency. Based on historical experience and review of our current project in process, we believe that adjustments from open audits will not have an effect on our financial position, results of operations or cash flows. We are using the expected cost-plus-margin approach as the suitable method for allocating transaction price to the performance obligations in the contract under ASC 606. |
Leases | Leases At contract inception, we determine if an arrangement is a lease. Operating leases are included in “Operating lease assets”, “Current operating lease liabilities” and “Long term operating lease liabilities” on the condensed consolidated balance sheets. At March 31, 2020 all of our operating lease obligations had expired or were terminated. We have no finance leases. Leases with an initial term of 12 months or less were not recorded on the condensed consolidated balance sheets. Operating lease expense was recognized on a straight-line basis over the lease term. We had lease agreements with lease and non-lease non-lease Operating lease assets and liabilities were recognized at January 1, 2019, based on the present value of the future minimum lease payments over the lease term. One of our leases contained rent escalation clauses that were factored into our determination of lease payments. Our leases did not provide an implicit rate; we used its incremental borrowing rate based on the information available at the lease commencement date to discount payments to the present value. One of our operating leases contained a renewal option. The exercise of this option was at our discretion. Lease terms included options to extend or terminate the lease when it is reasonably certain that we will exercise that option. |
Shipping and Handling Fees and Costs | Shipping and Handling Fees and Costs |
Warranties | Warranties We offer warranties generally ranging from one to five years, depending on the product and negotiated terms of purchase agreements with our customers. Such warranties require us to repair or replace defective products returned to us during such warranty period at no cost to the customer. An estimate by us for warranty related costs is recorded by us at the time of sale based on our actual historical product return rates and expected repair costs. Such costs have been within our expectations. |
Indemnities | Indemnities In connection with the sales and manufacturing of our commercial products, we indemnify, without limit or term, our customers and contract manufacturers against all claims, suits, demands, damages, liabilities, expenses, judgments, settlements and penalties arising from actual or alleged infringement or misappropriation of any intellectual property relating to our products or other claims arising from our products. We cannot reasonably develop an estimate of the maximum potential amount of payments that might be made under our indemnities because of the uncertainty as to whether a claim might arise and how much it might total. Historically, we have not incurred any expenses related to these indemnities. |
Research and Development Costs | Research and Development Costs Research and development costs are charged to expense as incurred and include salary, facility, depreciation and material expenses. Research and development costs are charged to research and development expense. |
Inventories | Inventories Inventories were stated at the lower of cost or net realizable value, with costs primarily determined using standard costs, which approximate actual costs utilizing the first-in, first-out |
Preferred equity interest interest in real estate | Preferred equity interest in real estate We entered into a Securities Purchase Agreement with Clearday, which was consummated on July 6, 2020, pursuant to which we an arm’s-length all-cash purchase |
Property and Equipment | Property and Equipment Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over their estimated useful lives ranging from three to five years. Leasehold improvements and assets financed under capital leases are amortized over the shorter of their useful lives. Furniture and fixtures are depreciated over seven years. Expenditures for additions and major improvements are capitalized. Expenditures for minor tooling, repairs and maintenance and minor improvements are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded in selling, general and administration expenses. During the three month period ending March 28, 2020 we ceased production of our Conductus wire and sold most of our production wire equipment for a gain of $510,000. There was no additional gain or loss in the three or nine month period ending September 26, 2020. |
Patents, Licenses and Purchased Technology | Patents, Licenses and Purchased Technology Patents and licenses are recorded at cost and are amortized using the straight-line method over the shorter of their estimated useful lives or seventeen years. During the three month period ending March 28, 2020 we ceased production of our Conductus wire and sold many Conductus wire patents for no gain or loss and we also recognized a $134,000 impairment of other patents. There was no additional gain or loss in the three or nine month period ending September 26, 2020. |
Other Assets and Investments | Other Assets and Investments The realizability of long-lived assets is evaluated periodically as events or circumstances indicate a possible inability to recover the carrying amount. Long-lived assets that will no longer be used in the business are written off in the period identified since they will no longer be used in operations and generate any positive cash flows for us. Periodically, long-lived assets that will continue to be used by us will need to be evaluated for recoverability. Such evaluation is based on various analyses, including cash flow and profitability projections, as well as alternative uses, such as government contracts or awards. The analyses necessarily involve significant management judgment. In the event the projected undiscounted cash flows are less than net book value of the assets, the carrying value of the assets will be written down to their estimated fair value. We tested our long-lived assets at September 26, 2020 and none of our long-lived assets were impaired. |
Loss Contingencies | Loss Contingencies In the normal course of our business, we are subject to claims and litigation, including allegations of patent infringement. Liabilities relating to these claims are recorded when it is determined that a loss is probable and the amount of the loss can be reasonably estimated. Legal fees are recorded as services are provided. The costs of our defense in such matters are charged to operations as incurred. Insurance proceeds recoverable are recorded when deemed probable. |
Income Taxes | Income Taxes We recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized. two-step more-likely-than-not No liabilities for uncertain tax positions were recorded in the current year. No interest or penalties on uncertain tax positions have been expensed to date. We are not under examination by any taxing authorities. Our federal statute of limitations for examination of us is open for 2016 and subsequent filings. Due to our operating losses, the 2017 Tax Act has not impacted our operating results or income tax expense. The primary impact of the 2017 Tax Act was the re-measurement As of December 31, 2019, we had net operating loss carryforwards for federal and state income tax purposes. We concluded that under the Internal Revenue Code change of control limitations, a maximum of $17.9 million of our $342.4 net operating loss carryforwards, which expire in the years 2020 through 2038, would be available for reduction of taxable income and reduced both the deferred tax asset and valuation allowance accordingly. Due to the uncertainty surrounding their realization, we recorded a full valuation allowance against our net deferred tax assets. Accordingly, no deferred tax asset has been recorded in the accompanying condensed consolidated balance sheets. |
Marketing Costs | Marketing Costs All costs related to marketing and advertising our products are charged to expense as incurred or at the time the advertising takes place. Advertising costs were not material in each of the three and nine months ended September 26, 2020 and September 28, 2019. |
Net Loss Per Share | Net Loss Per Share |
Stock-based Compensation Expense | Stock-based Compensation Expense We grant both restricted stock awards and stock options to our key employees, directors and consultants. For the three and nine months ended September 26, 2020 and September 28, 2019, no options or awards were granted. The following table presents details of total stock-based compensation expense that is included Three months ended Nine months ended September 26, September 28, September 26, September 28, Cost of revenue $ — $ 1,000 $ 2,000 $ 3,000 Research and development 3,000 2,000 7,000 7,000 Selling, general and administrative 19,000 20,000 56,000 60,000 Total stock-based compensation expense $ 22,000 $ 23,000 $ 65,000 $ 70,000 |
Use of Estimates | Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The significant estimates in the preparation of the financial statements relate to the assessment of the carrying amount of accounts receivable, fixed assets, intangibles, preferred equity interest in real estate, estimated provisions for warranty costs, income taxes and disclosures related to litigation. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments We have estimated the fair value amounts of our financial instruments using the available market information and valuation methodologies considered appropriate. We determined the book value of our cash and cash equivalents and other current liabilities as of September 26, 2020 approximate fair value. |
Comprehensive Income | Comprehensive Income We have no items of other comprehensive income in any period and consequently have not included a Statement of Comprehensive Income. |
Segment Information | Segment Information We have historically operated in a single business segment: the research, development, manufacture and marketing of high performance products used in cellular base stations. We derived net commercial product revenues primarily from the sales of our AmpLink and SuperPlex products which we sold directly to wireless network operators in the United States. Net revenues derived principally from government contracts are presented separately on the consolidated statements of operations for all periods presented. As discussed in this Report, we no longer have the ability to resume HTS wire operations without significant new investments and restructured operations and a new HTS wire business plan, neither of which we currently intend to pursue, as we instead focus our efforts on completing the Merger. |
Certain Risks and Uncertainties | Certain Risks and Uncertainties On October 29, 2019, we announced that our Board of Directors, supported by its management team, had commenced a process to explore strategic alternatives focused on maximizing shareholder value. Strategic alternatives considered included, among others, a strategic investment financing which would allow the company to pursue its current business plan to commercialize the Conductus wire platform, a business combination such as a merger with another party, or a sale of STI. On January 28, 2020, we announced a cost reduction plan for the purpose of aligning our personnel needs and capital requirements as we explored strategic alternatives previously announced. We will maintain operations of our Sapphire Cryocooler cryogenics initiatives while ceasing additional manufacturing of our HTS Conductus ® On February 26, 2020, we entered into a definitive merger agreement Clearday a privately-held company dedicated to delivering next generation longevity care and wellness services, whereby a wholly-owned subsidiary of STI will merge with and into Clearday in a stock-for-stock See “Our Future Business” above and “Subsequent Events” for more information. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 26, 2020 | |
Accounting Policies [Abstract] | |
Total Stock-Based Compensation Expense | The following table presents details of total stock-based compensation expense that is included Three months ended Nine months ended September 26, September 28, September 26, September 28, Cost of revenue $ — $ 1,000 $ 2,000 $ 3,000 Research and development 3,000 2,000 7,000 7,000 Selling, general and administrative 19,000 20,000 56,000 60,000 Total stock-based compensation expense $ 22,000 $ 23,000 $ 65,000 $ 70,000 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 9 Months Ended |
Sep. 26, 2020 | |
Equity [Abstract] | |
Summary of Stockholders' Equity Transactions | The following is a summary of stockholders’ equity transactions for the three and nine months ended September 26, 2020: Convertible Preferred Stock Common Stock Capital in Excess of Par Value Accumulated Deficit Shares Amount Shares Amount Total Balance at June 27, 2020 328,925 $ — 2,750,955 $ 3,000 $ 332,993,000 $ (330,796,000 ) $ 2,200,000 Issuance of common Stock for a preferred equity interest in real estate 400,000 — 1,600,000 1,600,000 Warrant exercises 828 — 2,000 2,000 Stock-based compensation 22,000 22,000 Cancellation of shares from the reverse stock split (3 ) — Net loss (606,000 ) (606,000 ) Balance at September 26, 2020 328,925 $ — 3,151,780 $ 3,000 $ 334,617,000 $ (331,402,000 ) $ 3,218,000 Convertible Preferred Stock Common Stock Capital in Excess of Par Value Accumulated Deficit Shares Amount Shares Amount Total Balance at December 31, 2019 328,925 $ — 1,773,189 $ 2,000 $ 330,474,000 $ (328,973,000 ) $ 1,503,000 Issuance of common Stock for a preferred equity interest in real estate 400,000 — 1,600,000 1,600,000 Warrant exercises 978,594 1,000 2,478,000 2,479,000 Stock-based compensation 65,000 65,000 Cancellation of shares from the reverse stock split (3 ) — Net loss (2,429,000 ) (2,429,000 ) Balance at September 26, 2020 328,925 $ — 3,151,780 $ 3,000 $ 334,617,000 $ (331,402,000 ) $ 3,218,000 The following is a summary of stockholders’ equity transactions for the three and nine months ended September 28, 2019: Convertible Common Stock Capital in Par Value Accumulated Deficit Shares Amount Shares Amount Total Balance at June 29, 2019 328,925 $ — 550,260 $ 1,000 $ 327,956,000 $ (324,670,000 ) $ 3,287,000 Issuance of common stock (net of costs) — Stock-based compensation 23,000 23,000 Net loss (2,375,000 ) (2,375,000 ) Balance at September 28, 2019 328,925 $ — 550,260 $ 1,000 $ 327,979,000 $ (327,045,000 ) $ 935,000 Convertible Common Stock Capital in Par Value Accumulated Deficit Shares Amount Shares Amount Total Balance at December 31, 2018 330,787 $ — 327,060 $ 1,000 $ 326,488,000 $ (319,744,000 ) $ 6,745,000 Conversion of Series E preferred stock to common stock (1,862 ) — 53,200 — — — Issuance of common stock (net of costs) 170,000 — 1,421,000 1,421,000 Stock-based compensation 70,000 70,000 Net loss (7,301,000 ) (7,301,000 ) Balance at September 28, 2019 328,925 $ — 550,260 $ 1,000 $ 327,979,000 $ (327,045,000 ) $ 935,000 |
Summary of Stock Option Transactions under Stock Option Plan | The following is a summary of stock option transactions under our Stock Option Plans at September 26, 2020: Number of Price Per Share Weighted Number of Weighted Balance at December 31, 2019 13,725 $ 19.20 - $51,480 $ 252.00 7,450 $ 448.10 Granted — Exercised — Canceled 5,862 $ 19.20 - $51,480 246.80 3,162 441.10 Balance at September 26, 2020 7,863 $ 19.20 - $28,440 $ 255.90 4,288 $ 453.30 |
Summary of Restricted Stock Award Transactions | The following is a summary of our restricted stock award transactions at September 26, 2020: Number of Weighted Average Grant Balance nonvested at December 31, 2019 33 $ 105.00 Granted — — Vested — — Forfeited — — Balance nonvested at September 26, 2020 33 $ 105.00 |
Summary of Outstanding Warrants | The following is a summary of outstanding warrants at September 26, 2020: Common Shares Total Currently Price per Expiration Date (1) Warrants related to October 2015 financing 13,552 13,552 $ 600.00 October 14, 2020 (2) Warrants related to October 2015 financing 903 903 $ 656.30 October 14, 2020 (3) Warrants related to August 2016 financing 5,350 5,350 $ 300.00 February 2, 2022 (4) Warrants related to August 2016 financing 500 500 $ 385.50 August 2, 2021 (5) Warrants related to December 2016 financing 68,567 68,567 $ 200.00 December 14, 2021 (6) Warrants related to March 2018 financing 15,810 15,810 $ 114.00 September 9, 2023 (7) Warrants related to March 2018 financing 1,107 1,107 $ 158.00 March 6, 2023 (8) Warrants related to July 2018 financing 257,143 257,143 $ 35.00 July 25, 2023 (9) Warrants related to July 2018 financing 15,428 15,428 $ 43.75 July 25, 2023 (10) Warrants related to May 2019 financing 11,900 11,900 $ 12.50 May 23, 2024 (11) Warrants related to October 2019 financing 217,200 217,200 $ 2.50 October 10, 2024 (12) Warrants related to October 2019 financing 30,916 30,916 $ 3.13 October 8, 2024 |
Loss Per Share (Tables)
Loss Per Share (Tables) | 9 Months Ended |
Sep. 26, 2020 | |
Earnings Per Share [Abstract] | |
Schedule of Antidilutive Shares Exercise or Vesting Excluded from Computation of Earnings (Loss) Per Share | Since their impact would be anti-dilutive, our net loss per common share does not include the effect of the assumed exercise or vesting of the following shares: September 26, September 28, Outstanding stock options 7,863 13,782 Unvested restricted stock awards 33 33 Outstanding warrants 638,376 391,414 Total 646,272 405,229 |
Details of Certain Financial _2
Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Activities (Tables) | 9 Months Ended |
Sep. 26, 2020 | |
Text Block [Abstract] | |
Components of Accounts Receivable | September 26, December 31, Accounts receivable: Accounts receivable-commercial products $ — $ 347,000 Less: allowance for doubtful accounts — (3,000 ) $ — $ 344,000 |
Components of Inventories | September 26, December 31, Inventories: Raw materials $ — $ 152,000 Work In Process 68,000 111,000 $ 68,000 $ 263,000 |
Components of Property and Equipment | September 26, December 31, Property and Equipment: Equipment $ 316,000 $ 11,911,000 Leasehold improvements — 1,065,000 Furniture and fixtures — 205,000 316,000 13,181,000 Less: accumulated depreciation and amortization (316,000 ) (12,948,000 ) $ — $ 233,000 |
Components of Patents and Licenses | September 26, December 31, Patents and Licenses: Patents pending $ — $ — Patents issued 278,000 1,712,000 Less accumulated amortization (278,000 ) (1,071,000 ) Net patents issued — 641,000 $ — $ 641,000 |
Components of Accrued Expenses and Other Long Term Liabilities | September 26, December 31, 2019 Accrued Expenses and Other Long Term Liabilities: Salaries Payable $ 14,000 $ 23,000 Compensated absences 90,000 211,000 Compensation related — 4,000 Warranty reserve — 8,000 Operating lease — 152,000 Other 30,000 54,000 134,000 452,000 Less current portion (134,000 ) (440,000 ) Long term portion $ — $ 12,000 |
Schedule of Warranty Reserve Activity | For the nine months ended, September 26, September 28, Warranty Reserve Activity: Beginning balance $ 8,000 $ 8,000 Additions — — Deductions 8,000 — Ending balance $ — $ 8,000 |
General - Additional Informatio
General - Additional Information (Detail) $ / shares in Units, $ in Millions | Jul. 06, 2020USD ($) | Jun. 30, 2020USD ($)$ / sharesshares | Jan. 28, 2020USD ($) | Nov. 30, 2016USD ($) | Sep. 26, 2020USD ($)Patentsshares | Dec. 31, 2019shares |
Number of patents generated | Patents | 100 | |||||
Research and development program award from U.S. Department of energy (DOE) | $ 4.5 | |||||
Percentage of Cost Reduction Employee Workforce | 70.00% | |||||
Expected aggregate sale value | $ 1.2 | |||||
Common stock issued | shares | 3,151,780 | 1,773,189 | ||||
Cmmon stock ,Value | $ 1.6 | |||||
Securities Purchase Agreement [Member] | ||||||
Common stock issued | shares | 400,000 | |||||
Cmmon stock ,Value | $ 1.6 | |||||
Common Stock purchase price | $ / shares | $ 4 | |||||
Merger Agreement [Member] | Minimum [Member] | ||||||
Net working capital | $ 250,000 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Additional Information (Detail) | Sep. 10, 2020 | Jul. 06, 2020USD ($)$ / sharesshares | Jan. 28, 2020 | Jul. 24, 2018 | Sep. 26, 2020USD ($)shares | Mar. 28, 2020USD ($) | Dec. 31, 2019USD ($) | Sep. 28, 2019USD ($)shares | Sep. 26, 2020USD ($)shares | Sep. 28, 2019USD ($)shares | Dec. 31, 2019USD ($) | Dec. 31, 2018USD ($) |
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Accumulated deficit | $ 331,402,000 | $ 328,973,000 | $ 331,402,000 | $ 328,973,000 | ||||||||
Incurred net loss | (606,000) | $ (2,375,000) | (2,429,000) | $ (7,301,000) | 9,200,000 | |||||||
Negative cash flows from operations | (2,652,000) | (6,762,000) | 8,800,000 | |||||||||
Cash and cash equivalents | 1,762,000 | 713,000 | $ 275,000 | 1,762,000 | $ 275,000 | 713,000 | $ 5,616,000 | |||||
Reverse split | 1-for-10 | 1-for-10 | ||||||||||
Reverse split conversion ratio | 0.1 | |||||||||||
Finance leases | 0 | 0 | ||||||||||
Inventory, net | 68,000 | 263,000 | $ 68,000 | 263,000 | ||||||||
Minimum percentage of tax benefit realized | 50.00% | |||||||||||
Liabilities for uncertain tax positions | 0 | $ 0 | ||||||||||
Interest or penalties on uncertain tax positions | $ 0 | |||||||||||
U.S. statutory corporate tax rate | 21.00% | |||||||||||
Deferred tax assets | $ 0 | 0 | $ 0 | 0 | ||||||||
Stock options granted during the period | shares | 0 | 0 | 0 | 0 | ||||||||
Warrants Exercise | $ 2,479,000 | |||||||||||
Percentage of Cost Reduction Employee Workforce | 70.00% | |||||||||||
Net cash proceedsfrom the sale of our common and preferred shares and warrants | 3,900,000 | |||||||||||
Wire inventory expensed | $ 190,000 | 190,000 | $ 0 | |||||||||
Gain on sale of production wire equipment | 510,000 | $ 510,000 | $ 0 | |||||||||
Common stock issued | shares | 400,000 | |||||||||||
Preferred equity interest, value | $ 1,600,000 | |||||||||||
Purchase price | $ / shares | $ 4 | |||||||||||
Warrants [Member] | ||||||||||||
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Warrant exercises, Shares | shares | 978,594 | |||||||||||
Warrants Exercise | $ 2,000,000,000 | 99,000 | $ 2,500,000 | |||||||||
Furniture and Fixtures [Member] | ||||||||||||
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Property, plant and equipment useful life | 7 years | |||||||||||
Patents and Licenses [Member] | ||||||||||||
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Estimated useful lives | 17 years | |||||||||||
Impairment of Intangible Assets | $ 134,000 | $ 0 | ||||||||||
Minimum [Member] | Equipment [Member] | ||||||||||||
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Property, plant and equipment useful life | 3 years | |||||||||||
Maximum [Member] | ||||||||||||
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Term of lease | 12 months | 12 months | ||||||||||
Maximum [Member] | Equipment [Member] | ||||||||||||
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Property, plant and equipment useful life | 5 years | |||||||||||
State [Member] | ||||||||||||
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Open tax year | 2013 | |||||||||||
State [Member] | Maximum [Member] | ||||||||||||
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Reduction of taxable income | 17,900,000 | |||||||||||
Federal [Member] | ||||||||||||
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Open tax year | 2014 | |||||||||||
Net operating loss carryforwards | $ 342.4 | $ 342.4 | ||||||||||
Earliest Tax Year [Member] | ||||||||||||
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Operating loss carryforwards expiration period | 2020 | |||||||||||
Latest Tax Year [Member] | ||||||||||||
Summary Of Significant Accounting Policies [Line Items] | ||||||||||||
Operating loss carryforwards expiration period | 2038 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Total Stock-Based Compensation Expense (Detail) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 26, 2020 | Sep. 28, 2019 | Sep. 26, 2020 | Sep. 28, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Total stock-based compensation expense | $ 22,000 | $ 23,000 | $ 65,000 | $ 70,000 |
Cost of Revenue [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Total stock-based compensation expense | 0 | 1,000 | 2,000 | 3,000 |
Research and Development [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Total stock-based compensation expense | 3,000 | 2,000 | 7,000 | 7,000 |
Selling, General and Administrative [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Total stock-based compensation expense | $ 19,000 | $ 20,000 | $ 56,000 | $ 60,000 |
Stockholders' Equity - Addition
Stockholders' Equity - Additional Information (Detail) | Jul. 06, 2020USD ($)$ / sharesshares | Oct. 10, 2019USD ($)$ / sharesshares | May 23, 2019USD ($)$ / sharesshares | Jul. 30, 2018USD ($)$ / sharesshares | Mar. 07, 2018USD ($)$ / shares | Sep. 26, 2020USD ($)$ / sharesPlanshares | Dec. 31, 2019USD ($)shares | Sep. 28, 2019USD ($)$ / sharesshares | Sep. 26, 2020USD ($)$ / sharesPlanshares | Sep. 28, 2019USD ($)$ / sharesshares | Sep. 28, 2020USD ($)$ / shares |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Number of equity award option plans | Plan | 2 | 2 | |||||||||
Impact on net loss | $ 22,000 | $ 23,000 | $ 65,000 | $ 70,000 | |||||||
Gross proceeds from common stock | $ 3,000,000 | $ 1,700,000 | $ 9,000,000 | $ 2,000,000 | |||||||
Net proceeds from common stock | $ 2,400,000 | $ 1,400,000 | $ 7,980,000 | $ 1,700,000 | $ 1,421,000 | ||||||
Warrants Exercise | $ 2,479,000 | ||||||||||
Common stock issued | shares | 400,000 | ||||||||||
Preferred equity interest, value | $ 1,600,000 | ||||||||||
Purchase price | $ / shares | $ 4 | ||||||||||
Securities Purchase Program [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Common stock issued | shares | 400,000 | ||||||||||
Preferred equity interest, value | $ 1,600,000 | ||||||||||
Purchase price | $ / shares | $ 4 | ||||||||||
Stock Options [Member] | Stock Option Plan [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Number of Shares, Exercised | shares | 0 | 0 | 0 | 0 | |||||||
Impact on net loss | $ 22,000 | $ 63,000 | $ 62,000 | $ 20,000 | |||||||
Impact on basic and diluted net loss per share | $ / shares | $ 0.01 | $ 0.03 | $ 0.14 | $ 0.04 | |||||||
Total compensation cost related to nonvested awards not yet recognized | $ 17,000 | $ 17,000 | |||||||||
Weighted-average period | 3 months | ||||||||||
Weighted-average contractual term of options outstanding | 7 years 8 months 12 days | ||||||||||
Weighted-average contractual term of stock options currently exercisable | 7 years 4 months 24 days | ||||||||||
Exercisable options with an exercise price less than the current market value | shares | 0 | 0 | |||||||||
Outstanding options expiration date | Oct. 31, 2028 | ||||||||||
Aggregate exercise price of options | $ 2,000,000 | ||||||||||
Minimum exercise price of options | $ / shares | $ 19.20 | ||||||||||
Maximum exercise price of options | $ / shares | $ 28,440 | ||||||||||
Restricted Stock [Member] | Stock Option Plan [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Impact on net loss | $ 0 | $ 3,000 | $ 2,000 | $ 8,000 | |||||||
Impact on basic and diluted net loss per share | $ / shares | $ 0 | $ 0.01 | $ 0 | $ 0.02 | |||||||
Total compensation cost related to nonvested awards not yet recognized | $ 0 | $ 0 | |||||||||
Stock compensation cost capitalized | $ 0 | ||||||||||
Restricted Stock [Member] | Minimum [Member] | Stock Option Plan [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Shares of restricted stock under awards all have service conditions and vest over | 1 year | ||||||||||
Restricted Stock [Member] | Maximum [Member] | Stock Option Plan [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Shares of restricted stock under awards all have service conditions and vest over | 3 years | ||||||||||
(11) Warrants Related to October 2019 financing [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants outstanding | shares | 1,183,400 | 217,200 | 217,200 | ||||||||
Warrants, exercisable period | 5 years | ||||||||||
Exercise price of warrants | $ / shares | $ 2.50 | $ 2.50 | $ 2.50 | ||||||||
Common Shares, Expiration Date | Oct. 10, 2024 | ||||||||||
Number of Warrants Exercised | shares | 828 | 39,528 | 978,594 | ||||||||
(12) Warrants Related to October 2019 financing [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants outstanding | shares | 82,838 | 30,916 | 30,916 | ||||||||
Exercise price of warrants | $ / shares | $ 3.125 | $ 3.13 | $ 3.13 | ||||||||
Common Shares, Expiration Date | Oct. 8, 2024 | Oct. 8, 2024 | |||||||||
(9) Warrants related to July 2018 financing [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants outstanding | shares | 15,428 | 15,428 | 15,428 | ||||||||
Warrants, exercisable period | 5 years | 5 years 7 months 6 days | |||||||||
Exercise price of warrants | $ / shares | $ 43.75 | $ 114 | $ 43.75 | $ 43.75 | |||||||
Common Shares, Expiration Date | Jul. 25, 2023 | ||||||||||
(10) Warrants related to May 2019 financing [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants outstanding | shares | 170,000 | 11,900 | 11,900 | ||||||||
Exercise price of warrants | $ / shares | $ 12.50 | $ 12.50 | $ 12.50 | ||||||||
Common Shares, Expiration Date | May 23, 2024 | May 23, 2024 | |||||||||
(8) Warrants related to July 2018 financing [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants outstanding | shares | 257,142 | 257,143 | 257,143 | ||||||||
Exercise price of warrants | $ / shares | $ 35 | $ 35 | $ 35 | ||||||||
Common Shares, Expiration Date | Jul. 25, 2023 | Jul. 25, 2023 | |||||||||
Common Stock [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Number of shares issued | shares | 1,183,400 | 11,900 | 257,142 | 170,000 | |||||||
Issuance price per share | $ / shares | $ 2.50 | $ 10 | $ 35 | ||||||||
Warrant [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||
Warrants Exercise | $ 2,000,000,000 | $ 99,000 | $ 2,500,000 |
Stockholders' Equity - Summary
Stockholders' Equity - Summary of Stockholders' Equity Transactions (Detail) - USD ($) | Oct. 10, 2019 | May 23, 2019 | Jul. 30, 2018 | Sep. 26, 2020 | Sep. 28, 2019 | Sep. 26, 2020 | Sep. 28, 2019 | Dec. 31, 2019 |
Beginning balance | $ 2,200,000 | $ 3,287,000 | $ 1,503,000 | $ 6,745,000 | $ 6,745,000 | |||
Issuance of common Stock for a preferred equity interest in real estate | 1,600,000 | 1,600,000 | ||||||
Issuance of common stock (net of costs) | 0 | 1,421,000 | ||||||
Warrant exercises | 2,000 | 2,479,000 | ||||||
Stock-based compensation | 22,000 | 23,000 | 65,000 | 70,000 | ||||
Net loss | (606,000) | (2,375,000) | (2,429,000) | (7,301,000) | 9,200,000 | |||
Ending balance | 3,218,000 | 935,000 | 3,218,000 | 935,000 | 1,503,000 | |||
Common Stock [Member] | ||||||||
Beginning balance | $ 3,000 | $ 1,000 | $ 2,000 | $ 1,000 | $ 1,000 | |||
Beginning balance, Shares | 2,750,955 | 550,260 | 1,773,189 | 327,060 | 327,060 | |||
Issuance of common Stock for a preferred equity interest in real estate, Shares | 400,000 | 400,000 | ||||||
Conversion of Series E preferred stock to common stock, Shares | 53,200 | |||||||
Conversion of Series E preferred stock to common stock | $ 0 | |||||||
Issuance of common stock (net of costs), Shares | 1,183,400 | 11,900 | 257,142 | 170,000 | ||||
Issuance of common stock (net of costs) | $ 0 | |||||||
Warrant exercises, Shares | 828 | 978,594 | ||||||
Warrant exercises | $ 0 | $ 1,000 | ||||||
Cancellation of common shares from reverse stock split, Shares | (3) | (3) | ||||||
Ending balance | $ 3,000 | $ 1,000 | $ 3,000 | $ 1,000 | $ 2,000 | |||
Ending balance, Shares | 3,151,780 | 550,260 | 3,151,780 | 550,260 | 1,773,189 | |||
Capital in Excess of Par Value [Member] | ||||||||
Beginning balance | $ 332,993,000 | $ 327,956,000 | $ 330,474,000 | $ 326,488,000 | $ 326,488,000 | |||
Issuance of common Stock for a preferred equity interest in real estate | 1,600,000 | 1,600,000 | ||||||
Conversion of Series E preferred stock to common stock | 0 | |||||||
Issuance of common stock (net of costs) | 1,421,000 | |||||||
Warrant exercises | 2,000 | 2,478,000 | ||||||
Stock-based compensation | 22,000 | 23,000 | 65,000 | 70,000 | ||||
Ending balance | 334,617,000 | 327,979,000 | 334,617,000 | 327,979,000 | 330,474,000 | |||
Accumulated Deficit [Member] | ||||||||
Beginning balance | (330,796,000) | (324,670,000) | (328,973,000) | (319,744,000) | (319,744,000) | |||
Net loss | (606,000) | (2,375,000) | (2,429,000) | (7,301,000) | ||||
Ending balance | $ (331,402,000) | $ (327,045,000) | $ (331,402,000) | $ (327,045,000) | $ (328,973,000) | |||
Convertible Preferred Stock [Member] | ||||||||
Beginning balance, Shares | 328,925 | 328,925 | 328,925 | 330,787 | 330,787 | |||
Conversion of Series E preferred stock to common stock, Shares | (1,862) | |||||||
Ending balance | $ 0 | $ 0 | ||||||
Ending balance, Shares | 328,925 | 328,925 | 328,925 | 328,925 | 328,925 |
Stockholders' Equity - Summar_2
Stockholders' Equity - Summary of Stock Option Transactions under Stock Option Plan (Detail) - $ / shares | 3 Months Ended | 9 Months Ended | |||
Sep. 26, 2020 | Sep. 28, 2019 | Sep. 26, 2020 | Sep. 28, 2019 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Number of Shares, Granted | 0 | 0 | 0 | 0 | |
Stock Option Plan [Member] | Stock Options [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Number of Shares, Beginning balance | 13,725 | ||||
Number of Shares, Granted | |||||
Number of Shares, Exercised | 0 | 0 | 0 | 0 | |
Number of Shares, Canceled | 5,862 | ||||
Number of Shares, Ending balance | 7,863 | 7,863 | |||
Weighted Average Exercise Price, Beginning Balance | $ 252 | ||||
Weighted Average Exercise Price, Canceled | 246.80 | ||||
Weighted Average Exercise Price, Ending Balance | $ 255.90 | $ 255.90 | |||
Number of Options Exercisable | 4,288 | 4,288 | 7,450 | ||
Number of Options Exercisable, Canceled | 3,162 | ||||
Weighted Average Exercise Price Exercisable | $ 453.30 | $ 453.30 | $ 448.10 | ||
Weighted Average Exercise Price Exercisable, Canceled | 441.10 | ||||
Stock Option Plan [Member] | Stock Options [Member] | Minimum [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Price Per Share, Beginning balance | $ 19.20 | ||||
Price Per Share, Canceled | 19.20 | ||||
Price Per Share, Ending balance | 19.20 | 19.20 | |||
Stock Option Plan [Member] | Stock Options [Member] | Maximum [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Price Per Share, Beginning balance | 51,480 | ||||
Price Per Share, Canceled | 51,480 | ||||
Price Per Share, Ending balance | $ 28,440 | $ 28,440 |
Stockholders' Equity - Summar_3
Stockholders' Equity - Summary of Restricted Stock Award Transactions (Detail) - Stock Option Plan [Member] - Restricted Stock [Member] | 9 Months Ended |
Sep. 26, 2020$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Number of Shares, Beginning balance | shares | 33 |
Number of Shares, Granted | shares | |
Number of Shares, Vested | shares | |
Number of Shares, Forfeited | shares | |
Number of Shares, Ending balance | shares | 33 |
Weighted Average Grant Date Fair Value, Beginning balance | $ / shares | $ 105 |
Weighted Average Grant Date Fair Value, Granted | $ / shares | |
Weighted Average Grant Date Fair Value, Vested | $ / shares | |
Weighted Average Grant Date Fair Value, Forfeited | $ / shares | |
Weighted Average Grant Date Fair Value, Ending balance | $ / shares | $ 105 |
Stockholders' Equity - Summar_4
Stockholders' Equity - Summary of Outstanding Warrants (Detail) - $ / shares | Oct. 10, 2019 | May 23, 2019 | Jul. 30, 2018 | Sep. 26, 2020 | Mar. 07, 2018 |
(1) Warrants related to October 2015 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 13,552 | ||||
Common Shares, Currently Exercisable | 13,552 | ||||
Common Shares, Price per Share | $ 600 | ||||
Common Shares, Expiration Date | Oct. 14, 2020 | ||||
(2) Warrants related to October 2015 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 903 | ||||
Common Shares, Currently Exercisable | 903 | ||||
Common Shares, Price per Share | $ 656.30 | ||||
Common Shares, Expiration Date | Oct. 14, 2020 | ||||
(3) Warrants related to August 2016 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 5,350 | ||||
Common Shares, Currently Exercisable | 5,350 | ||||
Common Shares, Price per Share | $ 300 | ||||
Common Shares, Expiration Date | Feb. 2, 2022 | ||||
(4) Warrants related to August 2016 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 500 | ||||
Common Shares, Currently Exercisable | 500 | ||||
Common Shares, Price per Share | $ 385.50 | ||||
Common Shares, Expiration Date | Aug. 2, 2021 | ||||
(5) Warrants related to December 2016 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 68,567 | ||||
Common Shares, Currently Exercisable | 68,567 | ||||
Common Shares, Price per Share | $ 200 | ||||
Common Shares, Expiration Date | Dec. 14, 2021 | ||||
(6) Warrants related to March 2018 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 15,810 | ||||
Common Shares, Currently Exercisable | 15,810 | ||||
Common Shares, Price per Share | $ 114 | ||||
Common Shares, Expiration Date | Sep. 9, 2023 | ||||
(7) Warrants related to March 2018 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 1,107 | ||||
Common Shares, Currently Exercisable | 1,107 | ||||
Common Shares, Price per Share | $ 158 | ||||
Common Shares, Expiration Date | Mar. 6, 2023 | ||||
(8) Warrants related to July 2018 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 257,142 | 257,143 | |||
Common Shares, Currently Exercisable | 257,143 | ||||
Common Shares, Price per Share | $ 35 | $ 35 | |||
Common Shares, Expiration Date | Jul. 25, 2023 | Jul. 25, 2023 | |||
(9) Warrants related to July 2018 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 15,428 | 15,428 | |||
Common Shares, Currently Exercisable | 15,428 | ||||
Common Shares, Price per Share | $ 43.75 | $ 43.75 | $ 114 | ||
Common Shares, Expiration Date | Jul. 25, 2023 | ||||
(10) Warrants related to May 2019 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 170,000 | 11,900 | |||
Common Shares, Currently Exercisable | 11,900 | ||||
Common Shares, Price per Share | $ 12.50 | $ 12.50 | |||
Common Shares, Expiration Date | May 23, 2024 | May 23, 2024 | |||
(11) Warrants related to October 2019 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 1,183,400 | 217,200 | |||
Common Shares, Currently Exercisable | 217,200 | ||||
Common Shares, Price per Share | $ 2.50 | $ 2.50 | |||
Common Shares, Expiration Date | Oct. 10, 2024 | ||||
(12) Warrants related to October 2019 financing | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Warrants outstanding | 82,838 | 30,916 | |||
Common Shares, Currently Exercisable | 30,916 | ||||
Common Shares, Price per Share | $ 3.125 | $ 3.13 | |||
Common Shares, Expiration Date | Oct. 8, 2024 | Oct. 8, 2024 |
Loss Per Share - Schedule of An
Loss Per Share - Schedule of Antidilutive Shares Exercise or Vesting Excluded from Computation of Earnings (Loss) Per Share (Detail) - shares | 9 Months Ended | |
Sep. 26, 2020 | Sep. 28, 2019 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 646,272 | 405,229 |
Outstanding stock options [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 7,863 | 13,782 |
Unvested restricted stock awards [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 33 | 33 |
Outstanding warrants [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 638,376 | 391,414 |
Loss Per Share - Additional Inf
Loss Per Share - Additional Information (Detail) - shares | 9 Months Ended | |
Sep. 26, 2020 | Sep. 28, 2019 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Conversion of preferred stock to common stock | 646,272 | 405,229 |
Convertible Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Conversion of preferred stock to common stock | 182 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) | Mar. 28, 2020USD ($) | Sep. 26, 2020USD ($) | Sep. 28, 2019USD ($) | Sep. 26, 2020USD ($)Renewals | Sep. 28, 2019USD ($) |
Other Commitments [Line Items] | |||||
Percentage of minimum royalty payment | 0.13% | ||||
Percentage of maximum royalty payment | 2.50% | ||||
Royalty expense | $ 0 | $ 0 | $ 11,000 | $ 10,000 | |
Operating lease expense | 0 | 143,000 | |||
License Obligations | $ 10,000 | $ 10,000 | |||
Operating lease obligations | $ 0 | ||||
Texas [Member] | |||||
Other Commitments [Line Items] | |||||
Operating lease expiration date | Mar. 31, 2020 | ||||
Renewal period of operating lease | 5 years | 5 years | |||
Number of five-year renewal option | Renewals | 1 | ||||
Minimum [Member] | |||||
Other Commitments [Line Items] | |||||
Royalty obligations termination period | 2020 | ||||
Maximum [Member] | |||||
Other Commitments [Line Items] | |||||
Royalty obligations termination period | 2025 |
Details of Certain Financial _3
Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Activities - Components of Accounts Receivable (Detail) - USD ($) | Sep. 26, 2020 | Dec. 31, 2019 |
Receivables [Abstract] | ||
Accounts receivable-commercial products | $ 347,000 | |
Less: allowance for doubtful accounts | (3,000) | |
Accounts receivable, net | $ 344,000 |
Details of Certain Financial _4
Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Activities - Components of Inventories (Detail) - USD ($) | Sep. 26, 2020 | Dec. 31, 2019 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 152,000 | |
Work In Process | 68,000 | 111,000 |
Inventories, net | $ 68,000 | $ 263,000 |
Details of Certain Financial _5
Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Activities - Components of Property and Equipment (Detail) - USD ($) | Sep. 26, 2020 | Dec. 31, 2019 |
Property, Plant and Equipment [Line Items] | ||
Property and Equipment, Gross | $ 316,000 | $ 13,181,000 |
Less: accumulated depreciation and amortization | (316,000) | (12,948,000) |
Property and Equipment, Net | 233,000 | |
Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment, Gross | 316,000 | 11,911,000 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment, Gross | 1,065,000 | |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment, Gross | $ 205,000 |
Details of Certain Financial _6
Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Activities - Additional Information (Detail) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 26, 2020 | Sep. 28, 2019 | Sep. 26, 2020 | Sep. 28, 2019 | |
Property, Plant and Equipment [Abstract] | ||||
Depreciation expense | $ 0 | $ 224,000 | $ 224,000 | $ 671,000 |
Amortization expense | 0 | $ 11,000 | 11,000 | $ 33,000 |
Amortization expense expected in 2020 | 0 | 0 | ||
Amortization expense expected in 2021 | 0 | 0 | ||
Amortization expense expected in 2022 | $ 0 | $ 0 |
Details of Certain Financial _7
Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Activities - Components of Patents and Licenses (Detail) - USD ($) | Sep. 26, 2020 | Dec. 31, 2019 |
Patents and Licenses: | ||
Patents and licenses, gross | ||
Patents and licenses, net | 641,000 | |
Patents Issued [Member] | ||
Patents and Licenses: | ||
Patents and licenses, gross | 278,000 | 1,712,000 |
Less accumulated amortization | (278,000) | (1,071,000) |
Patents and licenses, net | $ 641,000 |
Details of Certain Financial _8
Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Activities - Components of Accrued Expenses and Other Long Term Liabilities (Detail) - USD ($) | Sep. 26, 2020 | Dec. 31, 2019 | Sep. 28, 2019 | Dec. 31, 2018 |
Accrued Expenses and Other Long Term Liabilities: | ||||
Salaries Payable | $ 14,000 | $ 23,000 | ||
Compensated absences | 90,000 | 211,000 | ||
Compensation related | 4,000 | |||
Warranty reserve | 0 | 8,000 | $ 8,000 | $ 8,000 |
Operating lease | 152,000 | |||
Other | 30,000 | 54,000 | ||
Total | 134,000 | 452,000 | ||
Less current portion | (134,000) | (440,000) | ||
Long term portion | $ 12,000 |
Details of Certain Financial _9
Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Activities - Schedule of Warranty Reserve Activity (Detail) - USD ($) | 9 Months Ended | |
Sep. 26, 2020 | Sep. 28, 2019 | |
Product Warranties Disclosures [Abstract] | ||
Beginning balance | $ 8,000 | $ 8,000 |
Additions | 0 | 0 |
Deductions | 8,000 | 0 |
Ending balance | $ 0 | $ 8,000 |
Subsequent Events - Additional
Subsequent Events - Additional Information (Detail) - USD ($) | Sep. 26, 2020 | Jun. 27, 2020 | Feb. 27, 2020 | Dec. 31, 2019 | Sep. 28, 2019 | Jun. 29, 2019 | Dec. 31, 2018 |
Stockholders Equity | $ 3,218,000 | $ 2,200,000 | $ 1,503,000 | $ 935,000 | $ 3,287,000 | $ 6,745,000 | |
Minimum [Member] | Shareholder Equity Rule [Member] | |||||||
Stockholders Equity | $ 2,500,000 |